Skip to main content

Astria Therapeutics, Inc.

ATXSDelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001454789

Astria Therapeutics, Inc. was delisted in 2026; its insiders filed their last Form 4 on Jan 23, 2026; 141 institutions reported holding it in 13F filings for Q4 2025, worth $738.5M in total; Soros Fund Management was the only superinvestor holding it.

Key figures

Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
141
Q4 2025, +31 vs. previous quarter
13F value
$738.5M
Reported value at the end of Q4 2025
Superinvestors holding
1
At the end of Q4 2025

Superinvestors holding ATXS, Q4 2025

1 superinvestor reports holding Astria Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Go to the superinvestors tab

Soros Fund Management

George Soros

0.2%

Astria Therapeutics, Inc.'s share of the portfolio

Shares
873,400
Value
$11.4M

Latest insider trades

Open-market purchases and sales by Astria Therapeutics, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 3, 2024 (view filing)Apr 12 daysMorabito ChristopherChief Medical OfficerSSale−10.0K$13.59−$135.9K−100.0%0 after10b5-1
Feb 5, 2024 (view filing)5:02 PM ETFeb 14 daysEdelman Joseph and 3 othersDirectorPPurchase+2.48M$12.09+$30.0M+103.7%4.87M after
Jan 30, 2024 (view filing)Jan 26-294 daysMorabito ChristopherChief Medical OfficerSSale−10.0K$11.14−$111.4K−100.0%0 after2 lots10b5-1
Dec 22, 2023 (view filing)2:51 PM ETDec 211 dayEdelman Joseph and 3 othersDirectorPPurchase+740.0K$6.20+$4.59M+44.8%2.39M after
Oct 18, 2023 (view filing)4:11 PM ETOct 162 daysEdelman Joseph and 3 othersDirectorPPurchase+1.07M$6.51+$7.00M+200.1%1.61M after2 lots
Oct 18, 2023 (view filing)4:11 PM ETOct 162 daysEdelman Joseph and 3 othersDirectorPPurchase+2.42M$7.86+$19.0M–345.4K afterDerivative4 lots
Dec 21, 2022 (view filing)4:52 PM ETDec 192 daysEdelman Joseph and 3 othersDirectorPPurchase+908.3K$11.01+$10.0M+698.4%1.04M after
Nov 23, 2021 (view filing)Nov 194 daysKomjathy AndrewChief Commercial OfficerPPurchase+100$6.70+$670New position100 after

Top 10 13F holders, Q4 2025

The largest institutional positions in Astria Therapeutics, Inc. at the end of Q4 2025; share changes are against Q3 2025.

See all 141 holders
Institutions holding ATXS in Q4 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Perceptive Advisors LLC6,485,420$84.9M1.56%00.0%Unchanged
BlackRock, Inc.3,832,755$50.2M0.00%+344,553+9.9%Added
Glazer Capital, LLC3,776,154$49.4M1.30%+3,776,154New
Magnetar Financial LLC3,431,007$44.9M0.44%+3,431,007New
Vanguard Group Inc2,623,042$34.3M0.00%−19,128−0.7%Reduced
UBS Group AG2,399,171$31.4M0.01%+1,819,020+313.5%Added
Deutsche Bank AG1,762,802$23.1M0.01%+1,729,463+5,187.5%Added
Alliancebernstein L.P.1,732,464$22.7M0.01%+1,674,494+2,888.6%Added
Balyasny Asset Management LLC1,636,921$21.4M0.04%+1,636,921New
Geode Capital Management, LLC1,073,766$14.1M0.00%+115,522+12.1%Added